



Caffeine Citrate (Injection USP & Oral Solution USP)

Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)
Issue date: 2023-01-23 Version: 1.0

SECTION 1: Identification

1.1. Product identifier

Product form : Mixture
Product name : Caffeine Citrate (Injection USP & Oral Solution USP)

1.2. Recommended use and restrictions on use

Recommended use : Injection or Oral
Restrictions on use : No data available

1.3. Supplier

Omega Laboratories, Ltd.
11177 Hamon St.
Montreal, Quebec H3M 3E4
Canada
T (514) 335-0310

1.4. Emergency telephone number

Emergency number : (514) 335-0310

SECTION 2: Hazard identification

2.1. Classification of the substance or mixture

Classification (GHS CA)

Not classified

2.2. GHS Label elements, including precautionary statements

GHS CA labeling

No labeling applicable

2.3. Other hazards

No additional information available

2.4. Unknown acute toxicity (GHS CA)

No additional information available

SECTION 3: Composition/Information on ingredients

3.1. Substances

Not applicable

Caffeine Citrate (Injection USP & Oral Solution USP)

Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

3.2. Mixtures

Name	Chemical name / Synonyms	Product identifier	Conc. (% w/w)
Caffeine	Caffeine 1,3,7-Trimethylpurine-2,6-dione	CAS-No.: 58-08-2	1

Full text of hazard classes and H-statements : see section 16

SECTION 4: First-aid measures

4.1. Description of first aid measures

First-aid measures after inhalation	: Remove person to fresh air and keep comfortable for breathing. If you feel unwell, seek medical advice.
First-aid measures after skin contact	: Rinse skin with water/shower. Remove/Take off immediately all contaminated clothing. Wash contaminated clothing before reuse. If skin irritation or rash occurs: Get medical advice/attention.
First-aid measures after eye contact	: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.
First-aid measures after ingestion	: Get medical advice/attention. Rinse mouth out with water. Never give anything by mouth to an unconscious person.
First-aid measures general	: IF exposed or concerned: Get medical advice/attention.

4.2. Most important symptoms and effects (acute and delayed)

Symptoms/effects after inhalation	: May cause respiratory irritation.
Symptoms/effects after skin contact	: Repeated or prolonged contact may cause skin irritation.
Symptoms/effects after eye contact	: May cause eye irritation.
Symptoms/effects after ingestion	: May cause irritation to the digestive tract.

4.3. Immediate medical attention and special treatment, if necessary

Other medical advice or treatment	: Treat symptomatically.
-----------------------------------	--------------------------

SECTION 5: Fire-fighting measures

5.1. Suitable extinguishing media

Suitable extinguishing media	: Water spray. Dry powder. Foam. Carbon dioxide.
------------------------------	--

5.2. Unsuitable extinguishing media

Unsuitable extinguishing media	: No data available.
--------------------------------	----------------------

5.3. Specific hazards arising from the hazardous product

Fire hazard	: No fire hazard.
Hazardous decomposition products in case of fire	: Toxic fumes may be released.

5.4. Special protective equipment and precautions for fire-fighters

Protection during firefighting	: Do not attempt to take action without suitable protective equipment. Self-contained breathing apparatus. Complete protective clothing.
--------------------------------	--

Caffeine Citrate (Injection USP & Oral Solution USP)

Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

General measures : Ensure adequate ventilation. Wear personal protective equipment. Avoid breathing dust, mist or spray. Mark out the contaminated area with signs and prevent access to unauthorized personnel.

6.2. Methods and materials for containment and cleaning up

For containment : Stop leak, if possible without risk.
Methods for cleaning up : Take up liquid spill into absorbent material. Collect all waste in suitable and labeled containers and dispose according to local legislation.
Other information : Dispose of materials or solid residues at an authorized site.

6.3. Reference to other sections

For further information refer to section 8: "Exposure controls/personal protection"

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Precautions for safe handling : Ensure good ventilation of the work station. Wear personal protective equipment. Avoid contact with skin and eyes. Do not breathe gas, fumes, vapor or spray.
Hygiene measures : Handle in accordance with good industrial hygiene and safety procedures. Do not eat, drink or smoke when using this product. Always wash hands after handling the product.

7.2. Conditions for safe storage, including any incompatibilities

Storage conditions : Store in a well-ventilated place. Keep container tightly closed. Store at room temperature.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

No additional information available

8.2. Appropriate engineering controls

Appropriate engineering controls : Ensure good ventilation of the work station.
Environmental exposure controls : Avoid release to the environment.

8.3. Individual protection measures/Personal protective equipment

Hand protection:

Protective gloves

Eye protection:

Safety glasses

Skin and body protection:

Wear suitable protective clothing

Caffeine Citrate (Injection USP & Oral Solution USP)

Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

Respiratory protection:

Wear respiratory protection.

Personal protective equipment symbol(s):



SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state	: Liquid
Appearance	: Clear, colorless liquid.
Color	: Colorless
Odor	: No data available
Odor threshold	: No data available
pH	: 4.5 – 5.2
Relative evaporation rate (butyl acetate=1)	: No data available
Relative evaporation rate (ether=1)	: No data available
Melting point	: Not applicable
Freezing point	: No data available
Boiling point	: No data available
Flash point	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Flammability (solid, gas)	: Not applicable
Vapor pressure	: No data available
Relative vapor density at 20°C	: No data available
Relative density	: No data available
Density	: 1 g/ml
Solubility	: Miscible with water.
Partition coefficient n-octanol/water (Log Pow)	: No data available
Viscosity, kinematic	: No data available
Explosion limits	: No data available

9.2. Other information

No additional information available

SECTION 10: Stability and reactivity

Reactivity	: No additional information available
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: No dangerous reactions known under normal conditions of use.
Conditions to avoid	: No additional information available
Incompatible materials	: Strong acids. Strong bases. Strong oxidizing agents.
Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.
Hardening time:	: No additional information available

Caffeine Citrate (Injection USP & Oral Solution USP)

Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

SECTION 11: Toxicological information

11.1. Information on toxicological effects

Acute toxicity (oral) : Not classified
Acute toxicity (dermal) : Not classified
Acute toxicity (inhalation) : Not classified

Caffeine (58-08-2)	
LD50 oral rat	192 mg/kg
LD50 oral	185 mg/kg body weight Animal: mouse, Guideline: OECD Guideline 401 (Acute Oral Toxicity), 95% CL: 100 - 240
LD50 dermal rat	> 2000 mg/kg body weight Animal: rat, Guideline: OECD Guideline 402 (Acute Dermal Toxicity), Remarks on results: other:
LC50 Inhalation - Rat	≈ 4.94 mg/l air Animal: rat, Guideline: OECD Guideline 403 (Acute Inhalation Toxicity)
ATE CA (oral)	500 mg/kg body weight

Skin corrosion/irritation : Not classified
pH: 4.5 – 5.2
Serious eye damage/irritation : Not classified
pH: 4.5 – 5.2
Respiratory or skin sensitization : Not classified
Germ cell mutagenicity : Not classified
Carcinogenicity : Not classified

Caffeine (58-08-2)	
IARC group	3 - Not classifiable
Reproductive toxicity	: Not classified
STOT-single exposure	: Not classified
STOT-repeated exposure	: Not classified
Aspiration hazard	: Not classified
Likely routes of exposure	: Dermal. Ingestion. Inhalation.
Symptoms/effects after inhalation	: May cause respiratory irritation.
Symptoms/effects after skin contact	: Repeated or prolonged contact may cause skin irritation.
Symptoms/effects after eye contact	: May cause eye irritation.
Symptoms/effects after ingestion	: May cause irritation to the digestive tract.

SECTION 12: Ecological information

12.1. Toxicity

Hazardous to the aquatic environment, short-term (acute) : Not classified
Hazardous to the aquatic environment, long-term (chronic) : Not classified

Caffeine (58-08-2)	
LC50 - Fish [1]	≈ 87 mg/l Test organisms (species): Leuciscus idus
EC50 - Crustacea [1]	182 mg/l Test organisms (species): Daphnia magna
EC50 72h - Algae [1]	> 100 mg/l Test organisms (species): Desmodesmus subspicatus (previous name: Scenedesmus subspicatus)

Caffeine Citrate (Injection USP & Oral Solution USP)

Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

12.2. Persistence and degradability

Caffeine (58-08-2)

Persistence and degradability	Biodegradable in the soil.
-------------------------------	----------------------------

12.3. Bioaccumulative potential

Caffeine (58-08-2)

Bioaccumulative potential	Not bioaccumulative.
---------------------------	----------------------

Partition coefficient n-octanol/water (Log Pow)	-0.07
---	-------

12.4. Mobility in soil

Caffeine

12.5. Other adverse effects

Ozone : Not classified

SECTION 13: Disposal considerations

13.1. Disposal methods

Waste treatment methods : Dispose of contents/container in accordance with licensed collector's sorting instructions.

SECTION 14: Transport information

In accordance with TDG / DOT / IMDG / IATA

TDG	DOT	IMDG	IATA
14.1. UN number			
Not regulated for transport			
14.2. Proper Shipping Name			
Not applicable	Not applicable	Not applicable	Not applicable
Transport document description			
Not applicable	Not applicable	Not applicable	Not applicable
14.3. Transport hazard class(es)			
Not applicable	Not applicable	Not applicable	Not applicable
14.4. Packing group			
Not applicable	Not applicable	Not applicable	Not applicable
14.5. Environmental hazards			
Not applicable	Not applicable	Not applicable	Not applicable
No supplementary information available			

14.6. Special precautions for user

TDG

No data available

Caffeine Citrate (Injection USP & Oral Solution USP)

Safety Data Sheet

according to the Hazardous Products Regulation (February 11, 2015)

DOT

No data available

IMDG

No data available

IATA

No data available

14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

SECTION 15: Regulatory information

15.1. National regulations

Caffeine (58-08-2)

Listed on the Canadian DSL (Domestic Substances List)

SECTION 16: Other information

Issue date : 01-23-2023

Safety Data Sheet (SDS), Canada

This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.